Details: Keith Heigel, with Light-Heigel & Associates, who presented the plan, said the expansion would bring about 150 jobs ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program 12.09.2024 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement.

This material covers recent health news including Congo's expedited mpox vaccine launch, ACA's decade-long impact on US ...

Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...

Elsewhere in the small-cap space, Chariot, a Morocco-focused oil and gas group, appeared to deflate investor expectations ...

The global nicotine replacement products market is anticipated to reach USD 4.6 billion by 2033, with a compound annual growth rate (CAGR) of 4.8% from 2024 to 2033. The market growth is driven by ...

Elraglusib is a Class-Leading GSK-3ß Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company's ...